Michael Korenfeld, MD
Ophthalmology · Washington, MONPI 1174515613
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $35,015 of the $37,207 with a category attached, or 94.1%. Eyepoint US, Inc. accounts for 73.6% of it on its own, with 13 other manufacturers making up the rest. Reporting peaked in 2021 at $18,817 and has fallen 98.9% since, to $208 in 2025. Among ophthalmology clinicians in MO with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 45 payments — averaging $826.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eyepoint US, Inc.$27K
- Osmotica Pharmaceutical Corp.$6K
- Bausch Health US, LLC$2K
- Novartis$1K
- Tarsus Pharmaceuticals, Inc.$282
- Thea Pharma Inc.$232
- plus $565 from 8 others
Across 58 payments — averaging $13,973 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$457K
- Oyster Point Pharma, Inc.$166K
- Bausch Health US, LLC$106K
- Kala Pharmaceuticals, Inc.$33K
- Sun Pharmaceutical Industries Inc.$25K
- Glaukos Corporation$13K
- plus $10K from 1 others
What the payments were for
- Consulting fees$35,01594%
- Travel & lodging$1800%
- Food & beverage$1,8995%
- Other$1130%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eyepoint US, Inc. | 6 | $27,380 |
| Osmotica Pharmaceutical Corp. | 4 | $5,883 |
| Bausch Health US, LLC | 2 | $1,508 |
| Novartis | 7 | $1,358 |
| Tarsus Pharmaceuticals, Inc. | 2 | $282 |
| Thea Pharma Inc. | 7 | $232 |
| NEW World Medical,inc. | 5 | $185 |
| Johnson & Johnson | 1 | $113 |
| AbbVie(2 entities) | 2 | $108 |
| Alcon | 3 | $56 |
| Glaukos Corporation | 3 | $49 |
| Bausch & Lomb Americas Inc. | 1 | $22 |
| Sun Pharmaceutical Industries Inc. | 1 | $18 |
| Aerie Pharmaceuticals, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DEXYCU$26,900
- CVISC50$1,500
- YUTIQ$326
- XDEMVY$132
- Kahook Dual Blade$110
- Clearpath$110
- Ahmed Glaucoma Valve$110
- Streamline$110
How this compares
$37,207 in reported general payments places this provider in the 90th percentile of 286 ophthalmology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 74 | $37,443 |
| RocklatanNetarsudil Mesylat/Latanoprost | 61 | $24,611 |
| XiidraLifitegrast | 22 | $22,047 |
| RestasisCyclosporine | 11 | $15,357 |
| IlevroNepafenac | 33 | $12,659 |
| TyrvayaVarenicline Tartrate | 16 | $11,664 |
| Prednisolone Acetate | 434 | $11,136 |
| VyzultaLatanoprostene Bunod | 25 | $8,382 |
| Travoprost | 39 | $6,575 |
| Latanoprost | 476 | $5,392 |
| RhopressaNetarsudil Mesylate | 13 | $4,198 |
| Brimonidine Tartrate | 37 | $4,094 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 24 | $4,024 |
| Timolol Maleate | 219 | $2,179 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 30 | $1,273 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis | $108 | $52,80085 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $22 | $30,42947 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $15 | $28,81074 claims |
| NovartisIlevro | $1,358 | $12,65933 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 286 ophthalmology providers in Missouri.
Other ophthalmology in Washington
- Chris UllrichWashington$6K
- Steven SilversteinKansas City$872K
- Ranjan MalhotraSaint Louis$809K
- Nancy HolekampChesterfield$768K
- Jay PeposeChesterfield$516K
- Gregg BerdySaint Louis$360K
- Joseph GiraDes Peres$174K
- Joseph TauberKansas City$174K
- Jella AnColumbia$166K
- Shachar TauberSpringfield$150K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.